Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

Area of Science:

• Oncology
• Immunology

Background:

• Immune checkpoint blockers (ICBs) have transformed cancer treatment.
• Their application in hepatocellular carcinoma (HCC) is under active investigation, with some agents gaining accelerated approval.

Purpose of the Study:

• To review the safety and efficacy of ICBs in specific HCC patient populations.
• To identify patient groups who may not be ideal candidates for current ICB therapies.

Main Methods:

• Literature review of preclinical and clinical studies on ICBs in HCC.
• Analysis of safety data in patients with pre-existing autoimmune diseases, inflammatory bowel disease (IBD), or organ transplants.
• Evaluation of efficacy data in patients with non-alcoholic steatohepatitis (NASH) or specific molecular alterations (Wnt/β-catenin signaling).

Main Results:

• Atezolizumab plus bevacizumab has emerged as a new standard of care in first-line HCC treatment.
• Safety concerns exist for ICBs in patients with autoimmune conditions, IBD, or a history of organ transplantation.
• Emerging data suggest reduced efficacy of ICBs in patients with underlying NASH or HCCs exhibiting activated Wnt/β-catenin signaling.

Conclusions:

• While ICBs offer new therapeutic avenues for HCC, careful patient selection is crucial.
• Specific patient subgroups may require alternative treatment strategies due to safety or efficacy limitations.
• Further research is needed to optimize ICB use in diverse HCC patient populations.